P-078 - PHARMACOKINETICS AND EXPOSURE-RESPONSE ANALYSIS OF ABBV-321, AN EGFR-TARGETING ADC, IN PATIENTS WITH ADVANCED SOLID TUMORS.

K. Huang¹, N. Boehm², H. Gan³, B. Carneiro^4,5, R. Robinson⁶, M. Neagu Aristide¹, H. Atluri⁶, R. Menon¹; ¹AbbVie Inc., North Chicago, IL, USA, ²AbbVie Inc., Ludwigshafen, Germany, ³La Trobe University, Heidelberg, Melbourne, Australia, ⁴Brown University, Providence, RI, USA, ⁵Lifespan Cancer Institute at Rhode Island Hospital, Providence, RI, USA, ⁶AbbVie Inc., Redwood City, CA, USA.